Hackensack Meridian Health

Canary Speech is a technology company specializing in AI-driven vocal digital biomarkers for health monitoring through conversational speech. Its patented technology utilizes just 20 seconds of speech to analyze acoustic and linguistic features, enabling the detection of stress, mood, and energy levels before traditional clinical assessments. This innovative approach allows healthcare providers, payers, and patients to address conditions proactively, potentially reducing hospital readmissions and preventing unnecessary hospitalizations. Canary Speech's current research focuses on simulating various neurological and cognitive diseases, including Parkinson's, dementia, and Alzheimer's, providing significant implications for early diagnosis and intervention. By leveraging voice as a vital sign, Canary Speech is paving the way for advancements in machine learning applications within healthcare.

FluidForm Bio is a biotechnology company focused on creating living human tissue to enhance disease treatment. Utilizing its patented FRESH technology, the company specializes in 3D bioprinting, which enables the production of high-quality tissue that mimics real human tissue by integrating cells and proteins without additional materials. This innovative platform allows for the design and fabrication of complex tissue structures with embedded vasculature and multiple materials within a single print. Through collaborations with leading life science companies, FluidForm Bio's technology has been validated for various applications, paving the way for novel therapeutic programs in the healthcare sector. Founded in 2018 and headquartered in Waltham, Massachusetts, FluidForm Bio aims to provide better treatment options for patients through its transformational approach to tissue engineering.

Med-Metrix specializes in providing Performance Management and Revenue Cycle solutions tailored for the healthcare industry. The company’s services encompass patient intake, revenue integrity, collections, and business insights, all aimed at enhancing the productivity and financial performance of healthcare systems, hospitals, and providers. Utilizing its proprietary FLOWtechnology platform, Med-Metrix offers graphic-rich reporting and automated workflows, complemented by advisory and outsourcing services as necessary. This integrated approach enables clients to improve patient experiences while effectively increasing revenue collections.

EpiBone, Inc. is a biotechnology company based in Brooklyn, New York, focused on developing advanced solutions for bone and cartilage repair. Founded in 2013, EpiBone utilizes patient-specific scans and their own stem cells to create customized bone grafts, which are cultivated in a bioreactor to facilitate growth. The company aims to improve skeletal repair and enhance bone formation and regeneration through its innovative technologies. EpiBone's lead product, a living 3D bone graft, successfully completed its Phase I/IIa clinical trial in August 2023. Additionally, the company is advancing its cartilage repair pipeline, which includes an allogeneic osteochondral plug that received Investigational New Drug approval in July 2023, and an injectable cartilage filler, partly funded by the Department of Defense. Through these developments, EpiBone seeks to revolutionize orthopedic repair and provide patients with more effective treatment options.

Pillo Health specializes in providing tools for caregivers and health organizations to enhance care for individuals living at home. Central to its offerings is an intelligent healthcare assistant, Pillo, which manages medications and delivers health and wellness information directly to patients. The platform facilitates the proactive delivery of digital care plans and connects patients with care teams through notifications and video calls. Additionally, Pillo Health offers a software development kit (SDK) that allows partner organizations to create customized skills for the Pillo device, further adapting it to meet specific health management needs. Overall, the company aims to improve the longevity and quality of life for patients by ensuring they adhere to their care plans and maintain connections with healthcare providers.

COTA, Inc. is a Boston-based company that specializes in developing a platform designed to provide data and insights related to cancer patients, aimed at guiding treatment decisions. Founded in 2011 by a team of doctors, engineers, and data scientists, COTA utilizes proprietary technology and advanced analytics to transform fragmented electronic health record (EHR) data into cohesive, research-grade information. This platform supports oncology practices and cancer centers by identifying variations in care, thus enabling the design of effective treatment programs and payment models. COTA's solutions serve a diverse range of stakeholders, including healthcare providers, payers, life sciences companies, and the FDA, ultimately striving to enhance patient outcomes and reduce healthcare costs associated with cancer care.